666 related articles for article (PubMed ID: 22944438)
1. Investigation of inclusion complex of cilnidipine with hydroxypropyl-β-cyclodextrin.
Hu L; Zhang H; Song W; Gu D; Hu Q
Carbohydr Polym; 2012 Nov; 90(4):1719-24. PubMed ID: 22944438
[TBL] [Abstract][Full Text] [Related]
2. Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process.
Jun SW; Kim MS; Kim JS; Park HJ; Lee S; Woo JS; Hwang SJ
Eur J Pharm Biopharm; 2007 Jun; 66(3):413-21. PubMed ID: 17240129
[TBL] [Abstract][Full Text] [Related]
3. Inclusion complex of colchicine in hydroxypropyl-β-cyclodextrin tenders better solubility and improved pharmacokinetics.
Chauhan R; Madan J; Kaushik D; Sardana S; Pandey RS; Sharma R
Pharm Dev Technol; 2013; 18(2):313-22. PubMed ID: 21699389
[TBL] [Abstract][Full Text] [Related]
4. Curve-fitting FTIR studies of loratadine/hydroxypropyl-beta-cyclodextrin inclusion complex induced by co-grinding process.
Lin SY; Hsu CH; Sheu MT
J Pharm Biomed Anal; 2010 Nov; 53(3):799-803. PubMed ID: 20619996
[TBL] [Abstract][Full Text] [Related]
5. Studies on trimethoprim:hydroxypropyl-β-cyclodextrin: aggregate and complex formation.
Garnero C; Zoppi A; Genovese D; Longhi M
Carbohydr Res; 2010 Nov; 345(17):2550-6. PubMed ID: 20933225
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the 13-cis-retinoic acid/cyclodextrin inclusion complexes by phase solubility, photostability, physicochemical and computational analysis.
Yap KL; Liu X; Thenmozhiyal JC; Ho PC
Eur J Pharm Sci; 2005 May; 25(1):49-56. PubMed ID: 15854800
[TBL] [Abstract][Full Text] [Related]
7. Inclusion Complexation of Etodolac with Hydroxypropyl-beta-cyclodextrin and Auxiliary Agents: Formulation Characterization and Molecular Modeling Studies.
Sherje AP; Kulkarni V; Murahari M; Nayak UY; Bhat P; Suvarna V; Dravyakar B
Mol Pharm; 2017 Apr; 14(4):1231-1242. PubMed ID: 28248111
[TBL] [Abstract][Full Text] [Related]
8. Inclusion of Paracetamol into β-cyclodextrin nanocavities in solution and in the solid state.
El-Kemary M; Sobhy S; El-Daly S; Abdel-Shafi A
Spectrochim Acta A Mol Biomol Spectrosc; 2011 Sep; 79(5):1904-8. PubMed ID: 21703916
[TBL] [Abstract][Full Text] [Related]
9. Characterization and molecular modeling of the inclusion complexes of 2-(2-nitrovinyl) furan (G-0) with cyclodextrines.
Ruz V; Froeyen M; Busson R; González MM; Baudemprez L; Van den Mooter G
Int J Pharm; 2012 Dec; 439(1-2):275-85. PubMed ID: 22989977
[TBL] [Abstract][Full Text] [Related]
10. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
Badr-Eldin SM; Elkheshen SA; Ghorab MM
Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829
[TBL] [Abstract][Full Text] [Related]
11. Inclusion complexes of chlorzoxazone with β- and hydroxypropyl-β-cyclodextrin: Characterization, dissolution, and cytotoxicity.
Tang P; Li S; Wang L; Yang H; Yan J; Li H
Carbohydr Polym; 2015 Oct; 131():297-305. PubMed ID: 26256188
[TBL] [Abstract][Full Text] [Related]
12. Molecular simulation of hydroxypropyl-beta-cyclodextrin with hydrophobic selective Cox-II chemopreventive agent using host-guest phenomena.
Sinha VR; Nanda A; Chadha R; Goel H
Acta Pol Pharm; 2011; 68(4):585-92. PubMed ID: 21796941
[TBL] [Abstract][Full Text] [Related]
13. Preparation, characterization and in vivo evaluation of formulation of repaglinide with hydroxypropyl-β-cyclodextrin.
Liu M; Cao W; Sun Y; He Z
Int J Pharm; 2014 Dec; 477(1-2):159-66. PubMed ID: 25455768
[TBL] [Abstract][Full Text] [Related]
14. Alpinetin/hydroxypropyl-β-cyclodextrin host-guest system: preparation, characterization, inclusion mode, solubilization and stability.
Ma SX; Chen W; Yang XD; Zhang N; Wang SJ; Liu L; Yang LJ
J Pharm Biomed Anal; 2012; 67-68():193-200. PubMed ID: 22633603
[TBL] [Abstract][Full Text] [Related]
15. Sulfamethoxazole:hydroxypropyl-β-cyclodextrin complex: preparation and characterization.
Garnero C; Aiassa V; Longhi M
J Pharm Biomed Anal; 2012 Apr; 63():74-9. PubMed ID: 22361661
[TBL] [Abstract][Full Text] [Related]
16. Physicochemical characterisation of the supramolecular structure of luteolin/cyclodextrin inclusion complex.
Liu B; Li W; Zhao J; Liu Y; Zhu X; Liang G
Food Chem; 2013 Nov; 141(2):900-6. PubMed ID: 23790865
[TBL] [Abstract][Full Text] [Related]
17. Study of ascorbic acid interaction with hydroxypropyl-beta-cyclodextrin and triethanolamine, separately and in combination.
Garnero C; Longhi M
J Pharm Biomed Anal; 2007 Nov; 45(4):536-45. PubMed ID: 17851014
[TBL] [Abstract][Full Text] [Related]
18. Development and pharmacological evaluation of ropivacaine-2-hydroxypropyl-beta-cyclodextrin inclusion complex.
de Araujo DR; Tsuneda SS; Cereda CM; Del G F Carvalho F; Preté PS; Fernandes SA; Yokaichiya F; Franco MK; Mazzaro I; Fraceto LF; de F A Braga A; de Paula E
Eur J Pharm Sci; 2008 Jan; 33(1):60-71. PubMed ID: 18036789
[TBL] [Abstract][Full Text] [Related]
19. Drug product development and pharmacological evaluation of a sparingly soluble novel camptothecin analog for peroral administration.
Nekkanti V; Karatgi P; Paruchuri S; Pillai R
Drug Deliv; 2011 May; 18(4):294-303. PubMed ID: 21214430
[TBL] [Abstract][Full Text] [Related]
20. Inclusion complex of barbigerone with hydroxypropyl-β-cyclodextrin: preparation and in vitro evaluation.
Qiu N; Cheng X; Wang G; Wang W; Wen J; Zhang Y; Song H; Ma L; Wei Y; Peng A; Chen L
Carbohydr Polym; 2014 Jan; 101():623-30. PubMed ID: 24299819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
